2022
DOI: 10.1038/s41375-022-01582-5
|View full text |Cite
|
Sign up to set email alerts
|

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
56
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 89 publications
(68 citation statements)
references
References 24 publications
1
56
0
Order By: Relevance
“…The results of the study by Li et al [ 43 ] suggest that a dose of 8 g/m 2 might be beneficial for patients with PCNSL, although the optimal methotrexate dose has yet to be determined [ 18 , 48 ]. In comparison to HD-MTX alone, combining it with other chemotherapeutic agents might be beneficial [ 44 , 49 , 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…The results of the study by Li et al [ 43 ] suggest that a dose of 8 g/m 2 might be beneficial for patients with PCNSL, although the optimal methotrexate dose has yet to be determined [ 18 , 48 ]. In comparison to HD-MTX alone, combining it with other chemotherapeutic agents might be beneficial [ 44 , 49 , 50 ].…”
Section: Discussionmentioning
confidence: 99%
“…(6) WBRT might have a role as consolidation therapy in patients who did not achieve a CR after frontline treatment or those who cannot proceed to ASCT, especially when residual disease is confined to the CNS. (70,71) In the MARIETTA trial, 13 patients received WBRT: 7 of the 9 patients receiving WBRT (residual disease, n=5; poor mobilizers, n=2; after ASCT, n=2) after or during immunochemotherapy, to control responsive disease, achieved a complete or partial remission, and only one of them experienced relapse in the CNS; conversely, none of the four patients treated with WBRT for progressive disease responded. (52) As salvage therapy in SCNSL, earlier retrospective series showed responses in 67% -88% of patients including ~50% achieving CR with a 2-year OS of ~ 30%.…”
Section: Role Of Radiation Therapymentioning
confidence: 99%
“…Of note, there was one glioblastoma diagnosed 70 months after WBRT in the IELSG32 trial. 20 (3) Severe neurotoxicity concerns with repeat brain irradiation as salvage. 5…”
Section: Consolidation Strategies In Pcnslmentioning
confidence: 99%
“…Updated results, with a median follow-up time of 88 months, confirmed initial findings (reported after a median follow-up of 30 months) and encouragingly demonstrated a plateau in PFS beginning at approximately 5 years. 20 Three of the 60 patients (5%) who received ASCT developed secondary malignancies: carcinoma of the prostate, acute erythroid leukemia, and basal cell carcinoma.…”
Section: Consolidation Strategies In Pcnslmentioning
confidence: 99%
See 1 more Smart Citation